ADL
CDTX

Asset Dedication LLC’s Cidara Therapeutics CDTX Stock Holding History

Asset Dedication LLC’s Portfolio CDTX Stock Details CDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-88
Closed -$5K – 590
2019
Q1 		$5K Hold
88
– – ﹤0.01% 518
2018
Q4 		$4K Hold
88
– – ﹤0.01% 506
2018
Q3 		$8K Buy
+88
New +$7.76K ﹤0.01% 464

Other funds holding CDTX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
IVM
InterWest Venture Management San Francisco, California $20.6M AUM 48.5% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
AC
Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
ACM
Alethea Capital Management Mercer Island, Washington $195M AUM 51.17% 1-Year Est. Return
MIM
Monashee Investment Management Boston, Massachusetts $184M AUM 197.43% 1-Year Est. Return

Asset Dedication LLC's CDTX Position: Q2 2019 in Review

Asset Dedication LLC sold out of Cidara Therapeutics (CDTX) in Q2 2019, closing a stake of 88 shares — an estimated $5K sold.

Asset Dedication LLC first reported a position in CDTX in Q3 2018 and held it in 3 quarters. The position peaked at $8K in Q3 2018. 45 funds tracked by Wall St. Rank hold CDTX as of Q2 2019.

  • Asset Dedication LLC reported no remaining Cidara Therapeutics position as of Q2 2019 after selling out during the quarter.
  • Asset Dedication LLC sold 88 Cidara Therapeutics shares in Q2 2019, an estimated $5K.
  • Asset Dedication LLC first reported a position in Cidara Therapeutics in Q3 2018 and held it in 3 quarters.
  • Asset Dedication LLC's Cidara Therapeutics position peaked at $8K in Q3 2018.
  • 45 funds tracked by Wall St. Rank held Cidara Therapeutics as of Q2 2019.

Based on Asset Dedication LLC's 13F filing for Q2 2019, filed 23 Jul 2019.